Uptake of Sanofi's rights buyback indicates investors haven't written off Lemtrada…yet
This article was originally published in Scrip
Executive Summary
A short while back, Sanofi invited the holders of the contingent value rights (CVRs) it issued when it bought Genzyme to let it know the minimum price they would accept for those rights, if it were to pay $1.50-1.75 per CVR (representing a premium of 7-25% on the then market value of those CVRs).